Status:
ACTIVE_NOT_RECRUITING
Personalized Radiation Therapy for GBM
Lead Sponsor:
Abramson Cancer Center at Penn Medicine
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The study is a pilot study to estimate the efficacy of personalized dose-escalation radiation therapy in patients with glioblastoma, as measured by estimating the median of progression-free survival. ...
Eligibility Criteria
Inclusion
- Patients with biopsy-proven WHO Grade IV glioblastoma, after gross-total or near-total resection, who are undergoing definitive chemoradiation as part of their treatment regimen
- Age 18 or older
- Ability to give signed informed consent
- Karnofsky Performance Status (KPS) at least 70
Exclusion
- Placement of Gliadel wafers
- Participation in another investigational trial
- Active treatment of another malignancy
Key Trial Info
Start Date :
March 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03477513
Start Date
March 1 2018
End Date
July 30 2026
Last Update
June 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104